Pfizer (NYSE:PFE) EVP Charles Hill sold 96,500 shares of the stock on the open market in a transaction that occured on Wednesday, July 31st. The shares were sold at an average price of $29.64, for a total value of $2,860,260.00. Following the completion of the transaction, the executive vice president now directly owns 74,862 shares of the company’s stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Pfizer in a research note to investors on Wednesday. They now have a $31.00 price target on the stock. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Pfizer in a research note to investors on Wednesday, July 17th. Finally, analysts at Jefferies Group downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note to investors on Friday, July 12th. They now have a GBX 30 ($0.46) price target on the stock, down previously from GBX 32 ($0.49).
Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the stock. Pfizer currently has an average rating of “Buy” and a consensus target price of $30.75.
Shares of Pfizer (NYSE:PFE) traded down 0.41% during mid-day trading on Thursday, hitting $29.11. Pfizer has a one year low of $23.55 and a one year high of $31.15. The stock’s 50-day moving average is currently $28.6. The company has a market cap of $206.5 billion and a P/E ratio of 13.99.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $0.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.55 by $0.01. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $13.02 billion. During the same quarter in the prior year, the company posted $0.62 earnings per share. The company’s quarterly revenue was down 7.1% on a year-over-year basis. Analysts expect that Pfizer will post $2.17 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Wednesday, September 4th. Investors of record on Friday, August 2nd will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 3.30%. The ex-dividend date is Wednesday, July 31st.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.